Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) is the standard therapy, but response is heterogeneous and life expectancy is limited. The combined use of chemotherapeutic agents with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Valtorta, Silvia, Lo Dico, Alessia, Raccagni, Isabella, Gaglio, Daniela, Belloli, Sara, Politi, Letterio S, Martelli, Cristina, Diceglie, Cecilia, Bonanomi, Marcella, Ercoli, Giulia, Vaira, Valentina, Ottobrini, Luisa, Moresco, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762574/
https://www.ncbi.nlm.nih.gov/pubmed/29348889
http://dx.doi.org/10.18632/oncotarget.23028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762574/
https://www.ncbi.nlm.nih.gov/pubmed/29348889
http://dx.doi.org/10.18632/oncotarget.23028

Ejemplares similares